Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Home

Investor Home

As a biopharmaceutical company focused on creating cutting-edge therapies and technologies for patients with diabetes and orphan lung diseases, MannKind is on a mission to help people take control of their health. Our approved product, Afrezza® (insulin human) Inhalation Powder, is an ultra rapid-acting inhaled insulin that was approved by the U.S. FDA in June 2014 and became available by prescription in U.S. pharmacies in February 2015. Afrezza utilizes our proprietary Technosphere® Technology, an innovative, dry-powder formulation technology that allows medication to be delivered through the lungs.
investor FAQs
More FAQs are coming soon.

Data Provided by Refinitiv. Minimum 15 minutes delayed.